Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction.
about
Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-AnalysisEffects of ambient coarse, fine, and ultrafine particles and their biological constituents on systemic biomarkers: a controlled human exposure studyC-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study.Chlamydia pneumoniae and atherosclerosis.The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis from the Multi-Ethnic Study of AtherosclerosisChlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studiesChlamydia pneumoniae and other risk factors for atherosclerosis.The association of infection and coronary artery disease: an update.Helicobacter pylori-related diseases.The role of viruses in cardiac allograft vasculopathy.Chlamydia pneumoniae and coronary artery disease: legitimized linkages?Evaluation of the level of antibodies against Chlamydophila (Chlamydia) pneumoniae in post-surgery heart ischaemia patients and their clinical conditions - a six-year studyAn elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention.Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder.Chlamydophila pneumoniae infection and cardiovascular diseaseThe relationship between serum levels of hs-CRP and coronary lesion severityRole of C-reactive protein as a biomarker for renal cell carcinoma.Association of pathogen burden and hypertension: the Persian Gulf Healthy Heart Study.Microbial risk factors of cardiovascular and cerebrovascular diseases: potential therapeutical optionsUpdate of antibiotic trials for secondary prevention of coronary heart disease.Relation of Chlamydia pneumoniae infection to documented coronary artery disease in Shiraz, Southern Iran.Influence of periodontal intervention therapy on risk of cardiovascular disease.Immune activation as effect modifier of atherogenesis in chronic infection.C-reactive protein as a biomarker for urological cancers.Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.Coronary artery disease and periodontal disease: is there a link?Association between Helicobacter pylori infection and angiographically demonstrated coronary artery disease: A meta-analysis.C-reactive protein variations for different chronic somatic disorders.Serum N1-Methylnicotinamide is Associated With Coronary Artery Disease in Chinese Patients.Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants.The role of Chlamydia in coronary heart disease-fact or fiction?The role of immune activation in endotoxin-induced atherogenesis.Effect of treatment of chronic periodontitis on levels of serum markers of acute-phase inflammatory and vascular responses.Effects of hepatitis A vaccination on atherogenesis in a murine model.The short-term effects of treatment of chronic periodontitis on circulating levels of endotoxin, C-reactive protein, tumor necrosis factor-alpha, and interleukin-6.Chronic inflammatory autoimmune disorders and atherosclerosis.Expressions of interleukin-1β and interleukin-6 within aortas and uteri of rats with various severities of ligature-induced periodontitis.Soluble CD14 in periodontitis.Cytomegalovirus infection and coronary heart disease risk: a meta-analysis.Cytomegalovirus infection in a patient with systemic lupus erythematosus and acute myocardial infarction - cause or causal relationship?
P2860
Q26783046-67F4C0E1-73D6-4945-A289-63EB926404F9Q28645930-83692D79-F153-45A7-8402-C007521F721EQ30763122-C873A524-3A95-43DE-B6B3-7D2046506675Q33534714-F1F22D03-571A-4F68-83E8-79A329ED965DQ33749010-85E1AC79-4C5D-4FEE-819E-BC2C64506639Q33905858-8B7F9D56-DB63-47E7-8E2F-2B52067CA007Q33935014-2AF8529D-BFD4-4001-9F66-5F3779525FD5Q34075142-9A2E67E1-60E1-4ACC-8671-CF70A2E3B0C9Q34266402-A52C0469-96EE-4520-B465-C2687CCDAC87Q35671637-4883C2FF-6277-47BF-859C-EAAAE35367ABQ35696285-E513A3B2-CA44-43D9-B5C9-7AE3B6683A29Q35762026-B166F462-1F57-4F60-B2D5-3F01CD10D4DEQ35937166-411C6FFB-8260-448E-A25B-9D9B1A720C17Q36589670-3A0C3303-118B-4C30-B3CE-CD1497C6FBABQ36783331-6DA7E68D-DC17-478A-B96B-D219E2000067Q37187825-12A4F4D3-3171-4DBB-B70D-DB3E7781A442Q37812611-17E0BA5E-2DC2-4152-B1D5-0DAC826A17F2Q37846433-E9C65D8D-229D-40C1-AB62-38FEA70730D3Q37856198-A1C208C4-3983-4170-80D9-C9B7FF0FC999Q37865389-48345034-EED8-4C9F-948D-8D21004B526FQ37865613-8DCA65E5-D7EF-4F29-92BB-631A6E0E80CAQ37866360-F688EDF3-75F0-48E4-8216-04A84574FBC1Q37871384-6E93E0AC-ACE3-4776-8BFC-94173282FA88Q37949270-F1786BD3-543E-45DE-B52A-6B8D2DB3B413Q38035035-2E1EF4FF-6FFF-4411-83E0-E9F64F312D84Q38857727-0CCAB20E-DBF1-4A26-A314-2B4A22DF61DFQ38870083-AAA0E835-A74F-4CB4-B824-C47721C2549BQ40392144-B1C351A1-81F0-44D2-9E71-E1B7F3DF0D91Q41102388-DC66F4E4-41FE-49FA-AB62-DDE8AF5105B9Q41670268-095A33A1-C5B8-4784-8ED3-D8F45554BE12Q43427761-5ED790FD-859D-40A6-84CA-5764F079DAB4Q43805487-AC7803A5-C542-4F89-88B8-462FFDA470DFQ44402873-8FF40308-4D1A-48B9-BEC3-474D50998C1DQ44665738-47C1A449-9EE2-446F-9F33-B91525DA74AEQ44847449-D1443B3F-970E-4BD3-BFBF-65E2F4B8A70DQ46259292-19EDC6CA-0FE5-4779-85F0-22F7981395DBQ48340070-AFDED472-BA10-467D-859D-A508F086728CQ51752498-B8DF4ECC-9301-44F0-92A7-A0089B4111ACQ53095337-81E2DD95-440A-4E73-A8F2-288910A5C4F4Q55378508-72966726-36D6-45B9-BF00-E2DD3F7DD814
P2860
Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of C-reactive prote ...... ase and myocardial infarction.
@en
Evaluation of C-reactive prote ...... ase and myocardial infarction.
@nl
type
label
Evaluation of C-reactive prote ...... ase and myocardial infarction.
@en
Evaluation of C-reactive prote ...... ase and myocardial infarction.
@nl
prefLabel
Evaluation of C-reactive prote ...... ase and myocardial infarction.
@en
Evaluation of C-reactive prote ...... ase and myocardial infarction.
@nl
P2093
P1476
Evaluation of C-reactive prote ...... ase and myocardial infarction.
@en
P2093
Anderson JL
Carlquist JF
Muhlestein JB
P356
10.1016/S0735-1097(98)00203-4
P407
P577
1998-07-01T00:00:00Z